vonMinckwitz, G; Heidemann, E; Souchon, R; Samonigg, H; Hirschmann, WD; Bodenstein, H; Schindler, A; Schulze, M; Clemens, H; Konig, M; Scharl, A; Fischer, JT; Kaufmann, M.
Mitoxantrone (N) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line therapy in high-risk metastatic breast cancer
EUR J CANCER 1997 33: 646-646.
Web of Science